PFIZER INC (PFE) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-28..
Gross margin
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 63.70B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 17.08B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-28 | (m) | $63.70B | $17.08B | (m) |
| 2026-03-29 | (m) | $63.31B | $16.77B | (m) |
| 2025-12-31 | (m) | $62.58B | $16.07B | (m) |
| 2025-09-28 | (m) | $62.78B | $16.70B | (m) |
| 2025-06-29 | (m) | $63.83B | $17.80B | (m) |
| 2025-03-30 | (m) | $62.46B | $17.32B | (m) |
| 2024-12-31 | (m) | $63.63B | $17.85B | (m) |
| 2024-09-29 | (m) | $51.79B | $19.50B | (m) |
| 2024-06-30 | (m) | $47.58B | $23.51B | (m) |
| 2024-03-31 | (m) | $47.31B | $23.45B | (m) |
| 2023-12-31 | (m) | $50.91B | $24.95B | (m) |
| 2023-10-01 | (m) | $68.54B | $27.04B | (m) |
| 2023-07-02 | (m) | $77.94B | $23.83B | (m) |
| 2023-04-02 | (m) | $92.95B | $29.25B | (m) |
| 2022-12-31 | (m) | $100.33B | $34.34B | (m) |
| 2022-10-02 | (m) | $99.88B | $34.43B | (m) |
| 2022-07-03 | (m) | $101.28B | $38.30B | (m) |
| 2022-04-03 | (m) | $92.43B | $36.65B | (m) |
| 2021-12-31 | (m) | $81.29B | $30.82B | (m) |
| 2021-10-03 | (m) | $69.34B | $24.15B | (m) |
| 2021-07-04 | (m) | $55.52B | $16.18B | (m) |
| 2021-04-04 | (m) | $46.41B | $10.96B | (m) |
| 2020-12-31 | (m) | $41.91B | $8.69B | (m) |
| 2020-09-27 | (m) | $48.65B | $9.80B | (m) |
| 2020-06-28 | (m) | $49.20B | $9.87B | (m) |
| 2020-03-29 | (m) | $50.66B | $10.16B | (m) |
| 2019-12-31 | (m) | $51.75B | $10.22B | (m) |
| 2019-09-29 | (m) | $53.04B | $10.69B | (m) |
| 2019-06-30 | (m) | $53.66B | $10.78B | (m) |
| 2019-03-31 | (m) | $53.86B | $11.12B | (m) |
| 2018-12-31 | (m) | $53.65B | $11.25B | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-07-01 | (m) | (m) | (m) | (m) |
| 2018-04-01 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $52.55B | $11.23B | (m) |
| 2017-10-01 | (m) | (m) | (m) | (m) |
| 2017-07-02 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $52.82B | $12.32B | (m) |
| 2014-06-29 | (m) | $50.33B | (m) | (m) |
| 2014-03-30 | (m) | $50.53B | $9.37B | (m) |
| 2013-12-31 | (m) | $51.58B | $9.59B | (m) |
| 2013-09-29 | (m) | $56.25B | $11.06B | (m) |
| 2013-06-30 | (m) | $56.56B | $11.08B | (m) |
| 2013-03-31 | (m) | $57.60B | $11.24B | (m) |
| 2012-12-31 | (m) | $58.99B | $11.33B | (m) |
| 2012-09-30 | (m) | $62.23B | $12.80B | (m) |
| 2012-07-01 | (m) | $64.86B | $13.54B | (m) |
| 2012-04-01 | (m) | $66.33B | $14.37B | (m) |
| 2011-12-31 | (m) | $67.42B | $15.09B | (m) |
| 2011-10-02 | (m) | $68.24B | $15.46B | (m) |
| 2011-07-03 | (m) | $67.22B | $15.68B | (m) |
| 2011-04-03 | (m) | $67.73B | $15.77B | (m) |
| 2010-12-31 | (m) | $67.81B | $16.28B | (m) |
| 2010-10-03 | (m) | $66.78B | $15.93B | (m) |
| 2010-07-04 | (m) | $62.23B | $13.82B | (m) |
| 2010-04-04 | (m) | $55.89B | $11.79B | (m) |
| 2009-12-31 | (m) | $50.01B | $8.89B | (m) |
| 2009-09-27 | (m) | (m) | (m) | (m) |
| 2009-06-28 | (m) | (m) | (m) | (m) |
| 2009-03-29 | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $48.30B | $8.11B | (m) |
| 2008-09-28 | (m) | (m) | (m) | (m) |
| 2008-06-29 | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $48.42B | $11.24B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |